Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
06 sept. 2022 06h15 HE
|
MannKind
Study supports the dosing regimen that will be pursued in further clinical programsNo serious adverse events or QT prolongation identifiedPlanning underway to discuss results and the ongoing clinical...
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
01 sept. 2022 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
MannKind Corporation Reports 2022 Second Quarter Financial Results
09 août 2022 16h00 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere® inhalation platform V-Go® acquired May...
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
02 août 2022 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its...
MannKind Corporation to Participate in the BTIG Biotechnology Conference
01 août 2022 06h00 HE
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
03 juin 2022 10h00 HE
|
MannKind
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for...
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
24 mai 2022 06h00 HE
|
MannKind
Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere® inhalation technologyFirst approval of a dry powder inhaled treatment for PAH and PH-ILDManufacturing of Tyvaso...
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
19 mai 2022 06h00 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
17 mai 2022 06h06 HE
|
MannKind
The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE...
MannKind Corporation Participating at Upcoming Conferences
09 mai 2022 06h00 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...